YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Quick Read KYTX dropped 12% after JPMorgan trimmed its price target to $29, despite beating Q1 estimates and initiating a rolling BLA for miv-cel targeting a 2027 launch. BEAM slid 8% from a 52-week high and ALLO dropped 5%, while myasthen…
Cabaletta Bio, Inc. (NASDAQ:CABA) is one of the small-cap stocks with potential to rise 1000 percent. The company's 2026 story is focused on rese-cel, an experimental cell therapy being developed for autoimmune diseases, where the immune s…
Cabaletta Bio Inc. (NASDAQ:CABA) is one of the top penny stocks to buy in investors’ stock portfolio. On May 14, Cabaletta Bio Inc. (NASDAQ:CABA) delivered positive clinical and translational data from the first four patients in the lowest…
Company Logo The global Pemphigus Vulgaris (PV) market is witnessing significant growth, fueled by advancements in biologic therapies like rituximab, increased disease awareness, and improved healthcare access. While North America and Euro…
PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specific…
Cabaletta Bio PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies des…
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune…
[Female Healthcare professional prepares chemotherapy in a sterile hospital environment] wilpunt/E+ via Getty Images * Cellares said Wednesday that Cabaletta Bio’s (CABA [https://seekingalpha.com/symbol/CABA]) investigational CAR T therapy…
Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in November. Although overall economic growth h…
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patien…
(RTTNews) - Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting sharp gains. IO Biotech, Inc. (IOBT) surged 19.36% to $0.25 after announcing that i…
(RTTNews) - Shares of Cabaletta Bio, Inc. (CABA) are up nearly 6% at $2.33 in premarket trading on Tuesday. This late-stage clinical biotechnology company is focused on developing curative targeted cell therapies designed specifically for…
[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analysts last week identified 50 small-cap sto…
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AtriCure (ATRC) is a stock that can certainly grab the attention of many investors, but do its recent re…
The dynamics of the CAR T-cell therapy market are anticipated to change due to the extensive R&D activities, an increase in investment for research and development of the new CAR T-cell therapy, such as zamtocabtagene autoleucel (Miltenyi…
Cabaletta Bio – Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq…
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering s…
* Cabaletta Bio (NASDAQ:CABA [https://seekingalpha.com/symbol/CABA]) has filed [https://seekingalpha.com/filing/10277123]a registration statement with the SEC for a proposed $240M mixed securities offering. * This registration statement co…
– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program…
Cabaletta Bio, Inc. (NASDAQ:CABA), with a market capitalization of $106.17 million, is at the forefront of developing CAR-T therapies for autoimmune diseases, presenting a unique investment opportunity in the biotechnology sector. Accordin…
(RTTNews) - Cabaletta Bio, Inc. (CABA), a clinical-stage biotech firm developing targeted cell therapies for autoimmune diseases, has initiated an underwritten public offering of its common stock and accompanying warrants. Certain investor…
* Cabaletta Bio (NASDAQ:CABA [https://seekingalpha.com/symbol/CABA]) announced on Wednesday the pricing of an underwritten public offering consisting of 39.2 million shares of its common stock and accompanying warrants to purchase an aggre…
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies design…
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies design…
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding pati…
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients wit…
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Da…
The major averages were mostly lower near noon, with the Dow up fractionally but the Nasdaq down nearly 250 points amid mounting concerns about President Donald Trump’s upcoming announcement of promised new tariffs. Meanwhile, the S&P 500’…
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 20…
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these…
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients wi…
Overview of Recent Transaction On September 30, 2024, State Street Corp executed a significant transaction by reducing its holdings in Cabaletta Bio Inc (NASDAQ:CABA), a clinical-stage biotechnology company. The firm sold 1,109,678 shares…
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases…
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients – – Expanded CABA-201 clinical develop…
– First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases – – Clearance expands the clinical development of CABA-201…